Supernus Pharmaceuticals Investor Relations Material
Latest events
Study Update
Supernus Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Supernus Pharmaceuticals Inc
Access all reports
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its lead product candidate is Duopa (levodopa-carbidopa intestinal gel), a combination of levodopa and carbidopa for the treatment of Parkinson's disease in adults experiencing end-of-dose wearing off and end-of-dose dyskinesia; and ondansetron hydrochloride injectable suspension, which is being developed as a potential next generation form of treatment for chemotherapy-induced nausea and vomiting.
Key slides for Supernus Pharmaceuticals Inc
Study Update
Supernus Pharmaceuticals Inc
Status Update
Supernus Pharmaceuticals Inc
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
SUPN
Country
🇺🇸 United States